Skip Navigation


British Medical Bulletin Advance Access first published online on September 11, 2006
This version published online on October 5, 2006
British Medical Bulletin, doi:10.1093/bmb/ldl004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
77-78/1/5    most recent
ldl004v2
ldl004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kavanagh, D.
Right arrow Articles by Richards, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kavanagh, D.
Right arrow Articles by Richards, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. For Permissions, please email: journals.permissions@oxfordjournals.org

Atypical haemolytic uraemic syndrome

David Kavanagh1, Timothy H. J. Goodship2 and Anna Richards1,*

1 Washington University School of Medicine, St Louis, MO 63110, USA and
2 The Institute of Human Genetics, University of Newcastle upon Tyne NE1 3BZ, UK

* Correspondence to: Anna Richards, Washington University School of Medicine, Campus Box 8045, St Louis, MO 63110, USA. Tel.: +1 314 3628391; fax: 1 314 3621366; e-mail: anna.richards{at}ncl.ac.uk

The haemolytic uraemic syndrome (HUS) is characterized by the triad of thrombocytopenia, microangiopathic haemolytic anaemia and acute renal failure. HUS may be classified as either diarrhoeal-associated or non-diarrhoeal/atypical (aHUS). aHUS has recently been shown to be a disease of complement dysregulation, with 50% of cases involving the complement regulatory genes, factor H (CFH), membrane cofactor protein (MCP; CD46), and factor I (IF). However, incomplete penetrance of mutations in each of these genes is reported. This suggests that a precipitating event or trigger is required to unmask the complement regulatory deficiency. The reported precipitating events predominantly cause endothelial injury. Discovery of these mutations has revealed important genotype–phenotype correlations. MCP-HUS has a better prognosis and a better outcome after transplantation than either CFH-HUS or IF-HUS.

Keywords: atypical haemolytic uraemic syndrome (aHUS) • complement factor H (CFH) • membrane cofactor protein (MCP; CD46) • factor I (IF) • renal transplantation • thrombotic thrombocytopenic purpura (TTP)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.